Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 18/20 | 0.75 |
| ▸ | KDR | P35968 | 2/20 | 0.75 |
| ▸ | FBP1 | P09467 | 2/20 | 0.75 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.75 |
| ▸ | AURKA | O14965 | 1/20 | 0.75 |
| ▸ | INSR | P06213 | 1/20 | 0.75 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.75 |
| ▸ | FLT4 | P35916 | 1/20 | 0.75 |
| ▸ | CLK1 | P49759 | 1/20 | 0.75 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.75 |
| ▸ | TEK | Q02763 | 1/20 | 0.75 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.75 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29365524 | 1.00 | EGFR (0.75) | EGFRKDRFBP1ERBB2AURKA | |
| SCHEMBL29614965 | 1.00 | EGFR (0.75) | EGFRKDRFBP1ERBB2AURKA | |
| Hydrochloric Acid SCHEMBL641807 | 0.99 | EGFR (0.74) | EGFRKDRFBP1ERBB2AURKA | |
| SCHEMBL19006857 | 0.96 | EGFR (0.75) | EGFRKDRFBP1ERBB2AURKA | |
| SCHEMBL16212621 | 0.93 | EGFR (0.65) | EGFRKDRFBP1ERBB2AURKA | |
| SCHEMBL16212087 | 0.90 | FBP1 (0.76) | EGFRKDRFBP1ERBB2AURKA | |
| SCHEMBL642350 | 0.90 | EGFR (0.64) | EGFRKDRFBP1ERBB2AURKA | |
| SCHEMBL19293607 | 0.89 | FBP1 (0.66) | EGFRKDRFBP1ERBB2AURKA | |
| SCHEMBL17538495 | 0.89 | EGFR (0.63) | EGFRKDRFBP1ERBB2AURKA | |
| SCHEMBL16212227 | 0.89 | FBP1 (0.59) | EGFRKDRFBP1ERBB2AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 117 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113861120-A | Preparation method of dacomitinib | 湖南南新制药股份有限公司 | 2021-12-31 | — | — | CN | claimed |
| CN-111297865-A | Use of heterocyclic compound-containing composition for preparing medicine for treating lung cancer | 黄泳华 | 2020-06-19 | — | — | CN | claimed |
| US-20240382599-A1 | EGFR PROTEOLYSIS TARGETING CHIMERIC MOLECULES AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2024-11-21 | — | — | US | disclosed |
| CN-115850248-B | Tinich antitumor drug compound and preparation method and application thereof | 南京友怡医药科技有限公司 | 2024-07-02 | — | — | CN | disclosed |
| CN-117304170-A | Bifunctional molecule capable of degrading EGFR mutant and preparation method and application thereof | 中国药科大学 | 2023-12-29 | — | — | CN | disclosed |
| CN-114315595-B | Preparation method of carbon-supported iron-based catalyst and application of intermediate synthesis of anticancer inhibitor of carbon-supported iron-based catalyst | 奥锐特药业股份有限公司 | 2023-12-05 | — | — | CN | disclosed |
| WO-2023098592-A1 | PREPARATION METHOD FOR CARBON-LOADED IRON-BASED CATALYST AND USE THEREOF IN SYNTHESIS OF INTERMEDIATES OF ANTI-CANCER INHIBITORS | 奥锐特药业股份有限公司 | 2023-06-08 | — | — | WO | disclosed |
| CN-115850248-A | Teninil antitumor drug compound and preparation method and application thereof | 南京友怡医药科技有限公司 | 2023-03-28 | — | — | CN | disclosed |
| WO-2022184119-A1 | TYROSINE KINASE INHIBITOR AND PHARMACEUTICAL USE THEREOF | 江苏康可得生物技术股份有限公司 | 2022-09-09 | — | — | WO | disclosed |
| CN-114394942-A | Tyrosine kinase inhibitor and pharmaceutical application thereof | 江苏康可得生物技术股份有限公司 | 2022-04-26 | — | — | CN | disclosed |
| CN-114315595-A | Preparation method of carbon-supported iron-based catalyst and synthesis application of anti-cancer inhibitor intermediate thereof | 湖南大学 | 2022-04-12 | — | — | CN | disclosed |
| WO-2008033749-A2 | QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY | CURIS, INC. (US) | 2008-03-20 | — | — | WO | disclosed |
| WO-2008033747-A2 | MULTI-FUNCTIONAL SMALL MOLECULES AS ANTI-PROLIFERATIVE AGENTS | CURIS, INC. (US) | 2008-03-20 | — | — | WO | disclosed |
| EP-1746999-A1 | 4-PHENYLAMINO-QUINAZOLIN-6-YL-AMIDES | Warner-Lambert Company LLC (US) | 2007-01-31 | — | — | EP | disclosed |
| WO-2005107758-A1 | 4-PHENYLAMINO-QUINAZOLIN-6-YL-AMIDES | WARNER-LAMBERT COMPANY LLC (US) | 2005-11-17 | — | — | WO | disclosed |
| US-20050250761-A1 | such as -Piperidin-1-yl-but-2-enoic acid [4(3-chloro-4-fluoro-phenylamino)-7-methoxy-quinazolin-6-yl]-amide, used as tyrosine kinase inhibitors, for the prevention of proliferative diseases, including cancer, atherosclerosis, restenosis, endometriosis and psoriasis | PFIZER INC | 2005-11-10 | — | — | US | disclosed |
| US-5955464-A | USE OF THE RECEPTOR TYROSINE KINASE INHIBITORY PROPERTIES OF THE COMPOUNDS IN THE TREATMENT OF PROLIFERATIVE DISEASE SUCH AS CANCER | ZENECA LIMITED (GB) | 1999-09-21 | — | — | US | disclosed |
| EP-0794953-B1 | QUINAZOLINE DERIVATIVES | ZENECA LTD (GB) | 1999-05-06 | — | — | EP | disclosed |
| EP-0794953-A1 | QUINAZOLINE DERIVATIVES | ZENECA LIMITED (GB) | 1997-09-17 | — | — | EP | disclosed |
| WO-1996016960-A1 | QUINAZOLINE DERIVATIVES | ZENECA LIMITED (GB) | 1996-06-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240382599-A1 | EGFR PROTEOLYSIS TARGETING CHIMERIC MOLECULES AND ASSOCIATED METHODS OF USE | TBK1, EGFR, CBL | EGFR 2/4885KDR 241/4885FBP1 2591/4885 |
| US-20050250761-A1 | such as -Piperidin-1-yl-but-2-enoic acid [4(3-chloro-4-fluoro-phenylamino)-7-methoxy-quinazolin-6-yl]-amide, used as tyrosine kinase inhibitors, for the prevention of proliferative diseases, including cancer, atherosclerosis, restenosis, endometriosis and psoriasis | JAK1, JAK2, EDNRA | EGFR 41/4885KDR 503/4885FBP1 4696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.